In neuroblastoma (NB), expression of the TrkA receptor is correlated with good prognosis while N-myc amplification is correlated with poor prognosis. Decreased N-myc levels are key to controlling growth and inducing differentiation in NB cells. In this report, we detail mechanisms by which nerve growth factor (NGF) decreases N-myc levels in TrkA-transfected NB cells and its effect on NB cell proliferation. NGF induced a decrease in N-myc mRNA within 1 h of treatment that occurred in the presence of cycloheximide. The stability of N-myc mRNA was not affected by NGF, indicating a transcriptional control of N-myc mRNA by NGF. NGF but not brain-derived neurotrophic factor (BDNF) decreased N-myc levels demonstrating that p75 alone was not involved. The NGF-induced decrease in N-myc expression was blocked by the Trk tyrosine kinase (TK) antagonist K252a indicating that signals transduced by Trk TK downstream targets were involved. Pharmacologic inhibitors implicated the mitogen-activated protein kinase (MAPK) path. This was supported by the finding that expression of a constitutively activated component of the MAPK path, MAPK kinase (MEK), decreased Nmyc levels. Alterations in the level of N-myc are known to alter NB cell cycle progression by affecting the levels of E2Fs and p27 kip1 . Consistent with these findings, NGF decreased NB cell number and decreased cyclin Edependent kinase activity via an increase in p27 kip1 . Thus, our results indicate that the MAP kinase is selectively involved in the NGF-induced N-myc downregulation through a transcriptional mechanism. Furthermore, NGF affects the time required for 15N TrkA cells to complete a replication cycle by decreasing N-myc, E2Fs, cyclin E kinase activity and increasing p27 kip1 binding to cyclin E kinase.
In neuroblastoma (NB), expression of the TrkA receptor is correlated with good prognosis while N-myc amplification is correlated with poor prognosis. Decreased N-myc levels are key to controlling growth and inducing differentiation in NB cells. In this report, we detail mechanisms by which nerve growth factor (NGF) decreases N-myc levels in TrkA-transfected NB cells and its effect on NB cell proliferation. NGF induced a decrease in N-myc mRNA within 1 h of treatment that occurred in the presence of cycloheximide. The stability of N-myc mRNA was not affected by NGF, indicating a transcriptional control of N-myc mRNA by NGF. NGF but not brain-derived neurotrophic factor (BDNF) decreased N-myc levels demonstrating that p75 alone was not involved. The NGF-induced decrease in N-myc expression was blocked by the Trk tyrosine kinase (TK) antagonist K252a indicating that signals transduced by Trk TK downstream targets were involved. Pharmacologic inhibitors implicated the mitogen-activated protein kinase (MAPK) path. This was supported by the finding that expression of a constitutively activated component of the MAPK path, MAPK kinase (MEK), decreased Nmyc levels. Alterations in the level of N-myc are known to alter NB cell cycle progression by affecting the levels of E2Fs and p27 kip1 . Consistent with these findings, NGF decreased NB cell number and decreased cyclin Edependent kinase activity via an increase in p27 kip1 . Thus, our results indicate that the MAP kinase is selectively involved in the NGF-induced N-myc downregulation through a transcriptional mechanism. Furthermore, NGF affects the time required for 15N TrkA cells to complete a replication cycle by decreasing N-myc, E2Fs, cyclin E kinase activity and increasing p27 kip1 binding to cyclin E kinase.
Introduction
Neuroblastoma (NB) is a neural crest-derived tumor of the sympathetic nervous system that is one of the most common pediatric solid tumors. Several characteristics have been identified that predict the outcome of NB patients. In patients with a good prognosis, tumors occur in infants (o1 year), are aneuploid, lack loss of heterozygosity (LOH) at 1p or N-myc amplification and express relatively high levels of TrkA mRNA (Borello et al., 1993; Kogner et al., 1993; Nakagawara et al., 1993; Suzuki et al., 1993) . Indicators of poor prognosis include clinical presentation in older children (41 year) of tumors that are diploid, contain LOH at lp and amplification of the N-myc proto-oncogene. Tumors from patients with a poor prognosis express low to undetectable levels of TrkA, and TrkA expression inversely correlates with N-myc gene amplification (Nakagawara et al., 1993) . Despite the fact that most patients do very poorly, NB has one of the highest rates of spontaneous regression (Knudson and Meadows, 1980) . Furthermore, cell lines derived from patients with a poor prognosis can be induced to differentiate and decrease N-myc levels in vitro. These unique features have prompted a search for agents that can induce differentiation. Since downregulation of N-myc is an attractive target in N-myc amplified NB (Jain et al., 2002; Strieder and Lutz, 2002) , it is important to elucidate mechanisms of regulation of N-myc gene expression.
Most NB cell lines are derived from tumors of poor prognosis patients and although many of them have both low-and high-affinity nerve growth factor (NGF) receptors (Azar et al., 1990; Lavenius et al., 1995; Matsumoto et al., 1995) few differentiate in response to NGF stimulation (Hartman and Hertel, 1994) . TrkA levels can be increased in NB cells by the use of biologic response modifiers such as retinoic acid and interferong (Lucarelli et al., 1995) . When higher levels of p140-TrkA are achieved in NB cell lines by stable transfection of TrkA expression vectors, activation of the TrkA signal transduction path by NGF restores their ability to differentiate in response to NGF in vitro and in vivo. Moreover, differentiation is accompanied by decreases in N-myc mRNA and cell proliferation (Matsushima and Bogenmann, 1993; Lavenius et al., 1995; Poluha et al., 1995 Poluha et al., , 1996 . This suggests that the lack of response to NGF in TrkA-expressing NB cell lines may be due to the low levels of TrkA expression, rather than the previously proposed defect in the signal transduction pathway (Azar et al., 1990) .
Biologic response modifiers such as retinoids (Thiele et al., 1985) , 1,25-dihydroxyvitamine-D 3 (Veenstra et al., 1997) and iron chelation via desferoxamine mesylate (Fan et al., 2001) and NGF (Matsushima and Bogenmann, 1993) decrease N-myc gene expression in NB cells. Insulin-like growth factor (IGF) induces N-myc expression (Misawa et al., 2000) . Previously, we identified that retinoids induce a transcriptional decrease in N-myc mRNA (Thiele et al., 1988) and this was subsequently localized to a specific region in the Nmyc promoter (Wada et al., 1992) . Although NGF decreases N-myc mRNA expression (Bogenmann et al., 1998) , the NGF receptors (TrkA and p75) and signaling paths that mediate this have not been defined.
In the present study, we examine the mechanisms by which NGF regulates N-myc expression, the signaling pathways that mediate this decrease and its effects on NB cell cycle. We show that NGF utilizes TrkA, and not the p75 receptor, to decrease selectively N-myc expression and this is mediated by activation of the MAP kinase pathway. Furthermore, we find that the NGFinduced decrease in cell number is associated with a decrease in N-myc expression, a decrease E2F and a decrease in cyclin E kinase activity that is accompanied by increase in p27 kip changes in protein level and their binding to cyclin E.
Results

Functional analysis of TrkA-expressing NB cells
To evaluate the biologic consequences of activation of the NGF-TrkA signal transduction pathway in NB cells, the TrkA gene or a control vector was transfected into the LA1-15N (15N) and SMS-KCNR (KCNR) cell lines as described in Materials and methods. 15N cells did not secrete biologically relevant levels of NGF, since addition of 15N culture supernatant to the highly NGF-responsive PC-12 cells did not cause neurite extension (data not shown). Several independent clonal cell lines expressing gp140
TrkA were identified ( Figure 1a ) and selected clones analysed for activation of the TrkA signal transduction pathways. Autophosphorylation of gp140TrkA is one of the initial signaling events after NGF stimulation. The immunoprecipitated Trk proteins were then assayed for ligand-induced tyrosine phosphorylation by immunoblotting with anti-phosphotyrosine antibody. The NGF-treated 15N-EV and KCNR-EV (Empty Vector) cell lines do not have demonstrable NGF-stimulated gp140TrkA autophosphorylation ( Figure 1a) . In 15N clones E1, G3, G4 and KCNR-TrkA, autophosphorylation of gp140TrkA is detected after NGF treatment of cells (Figure 1a) .
To determine whether NGF activation of the TrkA receptor leads to changes in the downstream targets of TrkA signal transduction path, several TrkA-transfected clones were evaluated for NGF-stimulated early-response gene expression. NGF induced c-fos mRNA in 15N-TrkA-E1, G3 and G4 clones but not in 15N-EV (Figure 1b ). Densitometric analysis of appropriately exposed autoradiograms (with levels normalized to values obtained for GAPDH expression) indicated that a 30 min NGF treatment stimulated a 65-fold increase in c-fos expression in E1 cells which was still elevated after 9 h. NGF stimulates an early and transient increase in cfos mRNA in G3 and G4 cell lines at 1 h NGF treatment but not in 15N-EV.
Kinetics of N-myc expression in NGF-treated TrkA-expressing NB cells Since LA1-15N and SMS-KCNR cells contain amplified N-myc genes, the level of N-myc expression was determined in the 15N-EV, KCNR-EV and 15N clones E1, G3, G4 and KCNR-TrkA cells after treatment with NGF. NGF treatment decreased N-myc mRNA steadystate levels in 15N-TrkA E1, G3, G4 and KCNR-TrkA cells, but not in 15N-EV or KCNR-EV (Figure 2a ). Densitometric analysis (with levels normalized to values obtained for GAPDH expression) indicated that the decrease in N-myc mRNA was a relatively early event with a twofold decrease in N-myc mRNA occurring after 3 h of NGF treatment and an almost fourfold decrease after 9 h. By 72 h, the steady-state N-myc levels were decreased by 10-fold in NGF-treated 15N-TrkAE1 cells compared to control-treated cells (Figure 2a ). NGF treatment reduced N-myc expression by 50-60% after 1 h that decreased to 80% in TrkA-G3 cells at 24 h (Figure 2a) . NGF had little effect on N-myc mRNA 
Regulation of N-myc mRNA by NGF
Steady-state mRNA levels are influenced by the rate of gene transcription and/or by the stability of the mRNA transcripts. To evaluate the mechanisms by which NGF regulates N-myc gene expression, the stability of N-myc mRNA was determined in NGF-treated and control cells. G3 cells were treated for 90 min with 100 ng/ml NGF or control solvent. Subsequently, actinomycin-D (5 mg/ml) was added to the cultures to inhibit new mRNA synthesis, and the cells were incubated for the indicated times. Evaluation of N-myc mRNA stability following NGF treatment indicated that although the level of N-myc mRNA in NGF-treated cultures was lower than that detected in control cultures, there was no marked difference in the stability of N-myc mRNA isolated from these cultures under these condition (Figure 3a and b). To ascertain whether NGF-induced N-myc mRNA downregulation requires de novo protein synthesis, G3 cells were treated with NGF in the presence or absence of cycloheximide (CHX, 5 mg/ml), which inhibits new protein synthesis. Although the level of N-myc mRNA was dramatically increased, NGF induced a decrease in N-myc levels in the presence of CHX. This indicates that de novo protein synthesis was not required to mediate NGF-induced N-myc downregulation ( Figure 3c ). These findings suggest that the regulation of N-myc gene expression by NGF is at the transcriptional level in NB cells.
Activation of MAP kinase path decreases N-myc expression
The intracellular effects of NGF are mediated by the TrkA receptor tyrosine kinase or/and p75 (the panneurotrophin receptor), a member of the TNF family (Miller and Kaplan, 2000; Dechant, 2001) . To evaluate whether the p75 receptor was involved in the regulation of N-myc, cells were incubated with brain-derived neurotrophic factor (BDNF) that binds p75 but not TrkA. BDNF treatment did not decrease N-myc mRNA levels except when cells were treated with both BDNF and NGF (Figure 4a and b). These results indicate that signals transmitted through p75 alone do not regulate N-myc mRNA levels. To investigate whether the activation of TrkA is required for NGF-induced Nmyc downregulation, cells were treated for 1 h with K252a (with 1 mM), followed by treatment with NGF (100 ng/ml) for 1 h. RNA was extracted and evaluated by Northern blot analysis for N-myc and GAPDH expression. Inhibition of Trk tyrosine kinase blocked the ability of NGF to induce a decrease in N-myc mRNA levels. To investigate the Trk tyrosine kinase signal pathways by which NGF regulates N-myc levels, G3 cells were cultured with concentrations of inhibitors determined to block optimally the phosphatidylinositol- 3-kinase (PI-3-kinase), phospholipase Cg (PLCg) and mitogen-activated protein kinase (MAPK) pathways in NB cells as detailed in Materials and methods (data not shown). G3 cells were cultured with the indicated concentration of inhibitors prior to the addition of NGF. After 1 h in NGF, cells were harvested for total RNA isolation. NGF induced 50% decrease N-myc mRNA, compared with values obtained for controls (Figure 1a and b) . Although inhibition of the PI-3-kinase pathway (20 mM LY294002) led to a 50% decrease in the basal levels of N-myc, treatment with NGF induced a further 50% reduction in N-myc steadystate levels. NGF also decreased N-myc levels in G3 cells in which the PLCg pathway was blocked by U73122. However, NGF did not decrease N-myc levels in G3 cells treated with the MAPK kinase inhibitor (PD98059), indicating that the MAPK pathway is important in mediating the NGF-stimulated decrease in N-myc mRNA level. These studies indicate that PI-3-kinase, PLCg or p75 receptor pathways are not involved in NGF-induced N-myc mRNA downregulation. The finding that NGF-induced N-myc mRNA downregulation is abolished by addition of 100 mM PD98059 or 1 mM K252a, indicates that NGF-induced N-myc downregulation occurs via the MAPK pathway after NGF activation of the TrkA receptor.
To confirm that the activation of the MAPK pathway regulates N-myc expression, we overexpressed hemagglutinin (HA)-tagged wild-type MEK1 or an HA-tagged constitutively active type MEK1 mutant in LA1-15N and KCNR by transient transfection as described in Materials and methods. Because MAP kinases are direct downstream targets of MEK1, the activation of MAP kinases would be expected in cells expressing the constitutively active MEK1 mutants to cause a downregulation of N-myc levels. As predicted, in this study, we observed a correlation between MAPK phosphorylation and decreased N-myc expression in wild-typeand constitutively activated type MEK1-transfected lanes in LA1-15N and SMS-KCNR ( Figure 5 ). These results indicate that overexpression of wild-type or constitutively active MEK leads to activated MAPK and is associated with a decrease in N-myc levels.
Activation of TrkA pathways decreases cell number
Increased expression of N-myc shortens the G1 phase of the cell cycle and increases the rate of DNA synthesis and proliferation in NB cells (Lutz et al., 1996; Nakamura et al., 2003) . Thus, it is possible that a decrease in N-myc levels may prolong cell cycle progression. To assess cell proliferation, G3 cells were treated with 100 ng/ml NGF or control solvent. In the G3 clone tested, NGF caused decreased cell numbers compared to untreated cells ( Figure 6 ). There was no significant difference in viability in cultures when assessed by Trypan blue exclusion (data not shown). Furthermore, NGF treatment of 15N-TrkA G3 did not exert a demonstrable or sustained increase in the percentage of cells in any one particular phase of the cell cycle or change in cells with less than a G1 content of DNA (data not shown). These findings indicate that the NGF-induced decrease in cell number is not due to induction of cell death or arrest of cell cycle progression and suggest that NGF influences the time required for TrkA-expressing cells to undergo a replication cycle.
Since N-myc overexpression is known to shorten the G1 phase of the cell cycle, the decreased cell number may be due to a change in cell cycle regulatory genes (Lutz et al., 1996) . Cyclin E-associated kinase activity is rate limiting for progression into S phase (Sherr, 1993) and a general indicator of events in G1. Previously, we have shown that constitutive N-myc overexpression stimulates increases in cyclin E-dependent kinase activity by increasing cyclin E gene expression and decreasing p27 bound to cyclin E-dependent kinases (Nakamura et al., 2003) . Cyclin E kinase activity was assayed in 15N-TrkA G3 cell extracts after NGF addition. After 24 and 48 h, there was a decrease in the cyclin E kinase phosphorylation of histone H1 in NGF-treated 15N-TrkA G3 cells (Figure 7a ). Consistent with our previous results (Nakamura et al., 2003) , the decrease of cyclin E/cdk2 complex kinase activity is associated with decreased N-myc protein levels. To evaluate binding of p21 cip1 or p27 kip1 to the cyclin E, protein extracts of NGF-treated or -nontreated 15N-TrkA G3 cells were incubated with an excess of an anticyclin E antibody. The cyclin E immunoprecipitates were resolved by SDS-PAGE, transferred onto nitrocellulose, and Western analysis with anti-p27 kip1 and -p21 cip1 antibodies performed. An almost sevenfold increase in p27 kip1 binding to cyclin E was detected at 48 h after NGF treatment compared to controls (Figure 7a) , consistent with the increase in the levels of total p27 at this time (Figure 7b ). We did not detect p21 cip1 bound to cyclin E (data not shown) nor changes in total p21 or cyclin E levels (Figure 7b ). Taken together these results indicate that the decrease in cyclin E kinase activity was associated with a decrease in Nmyc and an increase in p27 protein levels and binding to cyclin E-dependent kinase.
NGF is known to regulate some members of the E2F family in PC12 cells (Persengiev et al., 1999 (Persengiev et al., , 2001 ) and recent evidence indicates that E2Fs can transcriptionally regulate N-myc levels (Strieder and Lutz, 2003) . We found that at 48 h NGF induced a 5.5-fold decrease in N-myc levels, a twofold decrease in E2F1 and a 2.8-fold decrease in E2F2 levels in 15N-TrkA (Figure 4b ). The decrease in E2F levels did not reach the extent or precede changes in N-myc levels; thus, it is not possible to assess whether the NGF-mediated decrease in N-myc is independent or dependent on changes in E2F levels.
Discussion
In this study we have examined the mechanism by which NGF regulates N-myc expression in NB and its effects on cell cycle progression. Experiments using the Trk receptor selective inhibitor K252a or preincubation with BDNF which neither decreases N-myc expression nor blocks the ability of NGF to decrease N-myc levels demonstrate that NGF-induced N-myc downregulation is mediated by TrkA and not by the p75 receptor ( Figure  4a and b) . Using pharmacological studies, we identified that basal N-myc levels were decreased by inhibition of the PI-3-kinase path. However, only inhibition of the MAP kinase path blocked the ability of NGF to decrease N-myc levels. Furthermore, to confirm the pharmacological result and extend our findings to another NB cell line, we transfected 15N and KCNR cells with vectors containing wild-type and constitutively activated type MEK and showed that decreased N-myc expression correlated with MAPK phosphorylation ( Figure 5 ). Our results provide the first evidence that the MAP kinase pathway is important for NGF/TrkA receptor-induced N-myc downregulation. We find that at least two distinct signaling mechanisms regulate Nmyc mRNA in N-myc-amplified NB cells. One is NGF/ TrkA/MAPK-stimulated N-myc downregulation, while the other is an NGF-independent PI-3-kinase pathway. In 10% fetal serum containing media, the basal level of N-myc gene expression was partially regulated by the (a) Immunoprecipitation (IP) of total protein cell lysates was carried out as described in Materials and methods using anti-cyclin E antibodies. After immunoprecipitation, the immunocomplexes were incubated with [g-32 P]ATP and the substrate (H1 histone) in an in vitro kinase assay. The substrate was separated from unincorporated [g-32 P]ATP by electrophoresis on a 10% Trisglycine gel. Immunoprecipitation of total protein cell lysates was carried out using anti-cyclin E antibodies. After immunoprecipitation, the immunocomplexes were analysed by SDS-PAGE analysis. The immunoblots (IB) were incubated with anti-p27 and anti-cyclin E antibodies. (b) Equal amounts of proteins from NGF-and control-treated cells (50 mg/lane) were analysed by SDS-PAGE analysis and transferred to nitrocellulose. The blots were incubated with anti-N-myc, anti-cyclin E, anti-E2F1, anti-E2F2, anti-p27, anti-p21 and anti-a-tubulin antibodies Figure 6 Effect of NGF on the proliferation rate of 15N-TrkA (G3). G3 cells were plated in duplicate at a density of 2 Â 10 5 cells per 100 mm tissue culture plate containing 10% FCS and after 24 h cells were treated with NGF (100 ng/ml). Cell number was monitored by collecting cells every 24 h and counting viable cells using Trypan blue exclusion and a hemocytometer (controldiamond; NGF-treated -square). Data represent mean and standard deviation from three independent counts for each time point from a representative experiment of two performed. Data are statistically significantly different from both control-and NGFtreated group as determined by a t-test. (**Po0.005, *Po0.02) PI-3-kinase pathway in our 15N-TrkA NB cells. It is possible that this NGF-independent N-myc regulation mechanism is associated with IGFI/II (insulin-like growth factor) signaling paths since IGFII is an important component of serum known to stimulate NB cell growth.
Recent studies (Chambery et al., 1999; Wittrock et al., 2002; Misawa et al., 2003) indicate a direct connection between IGF signaling and N-myc expression in NB with inhibition of PI-3-kinase blocking IGF-I induction of N-myc (Misawa et al., 2003) . However, these data also show that IGF-stimulated increases in N-myc expression are blocked by the MAPKK inhibitor (PD98059) and the farnesylation transferase inhibitor (FTI-277) (Misawa et al., 2000; Wittrock et al., 2002) . In our model (in which the effects of inhibitors were evaluated in 10% serum), PD98059 did not alter basal N-myc mRNA expression. This may be due to the differential sensitivity of serum-starved cells to IGF stimulation in other models compared to ours. However, we found that only PD98059 blocked NGFinduced N-myc downregulation (Figure 4a and b) indicating that NGF-induced N-myc downregulation is mediated via the MAPK pathway. This apparent discrepancy prompts the question of how different growth factors elicit distinct outcomes through common signal transduction paths. Despite sharing the involvement of the MAPK pathway to regulate N-myc gene expression, their outcomes are completely opposite. However, NGF specifically activates an MAPK pathway that uses the FRS2/C3G/Crk/Rap1/B-raf path (York et al., 1998; MacNicol and MacNicol, 1999; Ong et al., 2000; Kao et al., 2001; Wu et al., 2001) , while IGF or EGF (epidermal growth factor) stimulates an MAPK pathway that utilizes Shc/SOS/Ras/c-raf-1 (Skolnik et al., 1993; Kim et al., 1998; Kao et al., 2001) . Furthermore, IGFs may provoke a weak and transient activation of MAPKs, whereas NGF treatment results in sustained and robust activation of the signaling pathway. Wittrock et al. have shown that IGFII-stimulated N-myc expression is inhibited by FTI-277. However, FTI-277 did not inhibit phosphorylation of MAPK by NGF in our system (data not shown). This would indicate that differential utilization of G-proteins may distinguish an IGF/ras/c-raf/MAPK path that stimulates N-myc expression from the NGF/rap/B-raf/ MAPK path that inhibits N-myc expression.
Our study indicates that NGF alters the transcription of N-myc. This is based on the findings that N-myc mRNA levels decrease within 1 h of treatment, the stability of the N-myc mRNA does not change and Nmyc levels are decreased even in the absence of new protein synthesis in NGF-treated cells compared to controls (Figure 3a-c) . Taken together, these results would indicate that the NGF/TrkA/MAPK pathway mediates transcriptional repression of N-myc. Although the E2F (Strieder and Lutz, 2003) and the WT1 (Wilm's tumor 1) (Zhang et al., 1999) transcriptional factors have been identified as regulators of N-myc transcription, the regions of the N-myc promoter necessary to mediate alterations in N-myc expression stimulated by cell signaling pathways like IGF or NGF have not been identified. Interestingly, recent studies have shown that overexpression of PU1, a member of the Ets family and a MAPK downstream target, induced transcriptional repression of c-myc expression in murine erythroleukemia (MEL) cells (Kihara-Negashi et al., 2001 ). In addition, another Ets family member, Elk-1 which can be activated by MAPK pathway, transcriptionally represses c-myc expression through recruitment of corepressor complexes, like mSin3A-HDAC complex (Yang et al., 2002) . These findings suggest that a member of the Ets domain transcriptional factors may be involved in NGF-induced N-myc downregulation via MAPK path. There are several putative Ets binding DNA motifs in the N-myc promoter. Future experiments will map the region of the N-myc promoter that mediates NGF regulation and potential transcription factors that mediate this effect.
In this study, we found that NGF induced a decrease in cell number that was not due to cell cycle arrest or induction of cell death ( Figure 6 ). Furthermore, NGF treatment caused marked morphological changes resulting in 50-60% of cells with neurite extension in all 15N-TrkA clones. There were no morphological changes in NGF-treated 15N-EV cell line (data not shown). Aside from elaboration of neurites, there were fewer cells in NGF-treated 15N-TrkA compared to control cells, suggesting that NGF also altered cell number ( Figure 6 ). In PC12 cells, NGF-induced growth inhibition was accompanied by a decrease in the steady-state levels of cdk2, cdk6 and, to a lesser extent, cdk4 and their associated kinase activities. NGF-stimulated increases in p21 cip1 have been proposed to inhibit cyclindependent kinase activity and may be mediated by a sustained activation of MAPK (Decker, 1995; Dobashi et al., 1995; Billon et al., 1996; van Grunsven et al., 1996; Pumiglia and Decker, 1997; Bulseco et al., 2001; Tsygankova et al., 2001) . However, we did not detect changes in p21 (Figure 7b ) or cdk2, cdk4, cdk6 in 15N-TrkA cells after NGF treatment in our model (data not shown). In our study, NGF caused a decrease in cyclin E-dependent kinase activity that was associated with an increase in p27 kip1 levels and binding to cyclin Edependent kinases (Figure 7a and b) . This is similar to findings in RA-induced inhibition of NB cell growth in which RA induces a decrease in N-myc that is accompanied by an increase in p27 levels and binding to cyclin-dependent kinases resulting in decreased kinase activity (Matsuo and Thiele, 1998) . c-myc has also been shown to regulate cell cycle progression by modulating cyclin E kinase activity by antagonizing the function of p27 kip1 (Amati et al., 2001) . Recently, we found that there is an N-myc-dependent modulation of p27 kip1 levels as well as an N-myc-independent modulation of p27 kip1 levels. The N-myc-independent modulation of p27 kip1 levels is mediated by the levels of SKP-2, which targets p27 kip1 to the proteosome for degradation (Nakamura et al., 2003) . Since the levels of SKP-2 did not change in NGF/TrkA-treated NB cells (data not shown), the increases in p27 kip1 and decreases in cell number are most likely due to the decrease in N-myc levels. Other possible mediators of cell cycle progression are members of the E2F family of transcription factors (Adams et al., 2000; Beier et al., 2000; Berns et al., 2000; Santoni-Rugiu et al., 2000) . In our model, NGF treatment of TrkA-NB cells also induced a decrease in E2F levels. While increases in c-myc (Adams et al., 2000) and N-myc (Nakamura et al., 2003) stimulate E2Fs levels, recent evidence also indicates that E2Fs regulate N-myc transcription (Strieder and Lutz, 2003) . Future studies will be aimed at determining whether the NGFinduced decrease in cell number is due to decreases in Nmyc preceded or followed by decreases in E2F levels and whether NGF via MAPK activation affects cell cycle gene expression independent of changes in N-myc levels.
In conclusion, our results indicate that the MAP kinase path is selectively involved in the NGF-induced N-myc downregulation through a transcriptional mechanism. Furthermore, NGF affects the time required for 15N TrkA-positive cells to complete a replication cycle through decreases in N-myc, E2Fs and cyclin E kinase activity, and increases in the levels and binding of p27 kip1 to cyclin E-dependent kinases. By understanding the signal transduction pathways that regulate N-myc transcription, we may be able to identify additional mechanisms to decrease N-myc levels and alter the growth of N-myc-amplified NB cells.
Materials and methods
Cell lines and cell culture
The N-myc-amplified human NB cell lines, LA1-15N (15N) (Ciccarone et al., 1989) and SMS-KCNR (KCNR) (Reynolds et al., 1986) were electroporated with the vector pIRV Neo SV containing human TrkA or the empty vector alone at 250 V and 960 mF capacitance. Clonal cell lines containing TrkA, 15N-TrkA E1 (E1), 15N-TrkA G3 (G3), 15N-TrkA G4 (G4), and KCNR-TrkA or empty vector 15N-EV and KCNR-EV were isolated in 300 mg/ml geneticin G418 (Gibco BRL, Grand Island, NY, USA). These cells were cultured in RPMI-1640 containing 10% fetal calf serum, glutamine and penicillin and streptomycin.
Reagents and antibodies
Protein A agarose, the anti-p130 cas (SC-860), the anti-pan Trk (SC-11), the anti-pTyr monoclonal (SC-7020), anti-N-myc (SC-791), anti-cyclin E , anti-E2F1 (SC-251), anti-E2F2 (SC-632) and anti-p27 (SC-1641) and anti-HA antibody (SC-805) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Phospho-Akt (Ser473) antibody, phsopho-p44/42 MAP kinase (Thr202/Tyr204) antibody, LY294002 (PI-3-kinase inhibitor) and PD98059 (MAP kinase kinase inhibitor) were purchased from Cell Signaling Technology (Beverly, MA, USA). U73122 (PLCg inhibitor), anti-p21 (Ab-5) and K252a were purchased from Calbiochem (La Jolla, CA, USA). Anti-a-tubulin (Ab-1) was purchased from Oncogene Research Products (La Jolla, CA, USA). Actinomycin-D and cycloheximide were purchased from Sigma (St Louis, MO, USA).
Immunoprecipitation and immunoblotting
One million cells were plated into 100 mm tissue culture plates and incubated for 3 days at 371C and 5% CO2. Subsequently, cells were stimulated with 100 ng/ml NGF (Upstate Biotechnology, Lake Placid, NY, USA) for 5 min at 371C. After two washes with cold phosphate-buffered solution (PBS), total cell lysates were prepared in 1% Nonidet P-40 (NP-40) lysis buffer (1% NP-40, 20 mM Tris-HCl (pH 8.0), 500 mM sodium orthovanadate (pH 9.0), 140 mM NaCl, 10% glycerol, 10 mg aprotinin/ml, 1 mg leupeptin/ml, 1 mM phenylmethylsulfonyl fluoride) at 41C for 30 min. Insoluble material was removed by centrifugation at 41C for 15 min at 10 000 g. The lysates were immunoprecipitated with anti-pan Trk antibody. The immune complexes were then collected by rocking in 20 ml of 10% protein-A agarose beads (Santa Cruz) at 41C and washed three times with lysis buffer. Protein blots were incubated with antipTyr antibody (1 : 1000) for 1 h at room temperature. After washing membranes with Tris-buffered saline with Tween-20 (20 mM Tris-HCl (pH 7.4), 150 mM NaCl and 0.5% Tween-20), they were incubated with horseradish peroxidase-conjugated anti-mouse IgG (1 : 2000) for 1 h and analysed using an enhanced chemiluminescence (ECL) detection system (Amersham Corp., Piscataway, NJ, USA). Membranes were stripped with 2% SDS, 100 mM mercaptoethanol in 62.5 mM Tris-HCl (pH 6.8) for 30 min at 501C.
In vitro kinase assay
Control or NGF-treated G3 cell protein lysate was incubated with rabbit anti-cyclin E antibodies (SC-481, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). The immune complexes were then collected by rocking in 50 ml of 10% protein-A agarose beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) at 41C and washed four times with lysis buffer. The immunoprecipitates were either analysed for Western blotting using antibodies raised against p27 kip1 and cyclin E protein (SC-1641 and SC-198-G; Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) or used for in vitro kinase assay. For in vitro kinase assay, protein lysates (500 mg) were precleared with 10% protein-A agarose beads (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA). Kinase reaction was performed in 50 ml of kinase buffer with the addition of 10 mCi of [g-32 P]ATP and 5 mg of histone H1 (Roche, Indianapolis, IN, USA) at 301C for 30 min. Phosphorylated histone H1 were resolved by SDS-PAGE analysis and following electrophoresis, gels were fixed, dried and exposed to BioMax MS (Kodak, Rochester, NY, USA).
Evaluation of the effectiveness of each inhibitor to block each pathway in G3 cell PI-3-K activation, PLCg activation, MAPK activation and TrkA receptor activation by NGF and the effectiveness of 20 mM LY294002, 5 mM U73122, 100 mM PD98059 and 1 mM K252a to block each pathway in G3 cells were confirmed using the Western blot analysis for phosphorylation of the downstream target proteins (AKT, p130 CAS , MAPK and TrkA respectively) for each signal transduction pathway (data not shown). Cells were preincubated for 1 h with 20 mM LY294002 (PI-3-kinase inhibitor), 100 mM PD98059 (MAPKK inhibitor), 1 mM K252a (Trk receptor autophosphorylation inhibitor) and for 10 min with 5 mM U73122 (PLCg inhibitor) or human recombinant BDNF (100 ng/ml) (PeproTech Inc., Rocky Hill, NJ, USA) prior to NGF (100 ng/ml) treatment.
RNA extraction and Northern blot analysis
Cells were plated into 100 mm tissue culture dishes and incubated for 3 days at 371C and 5% CO2. Following the indicated treatment, cells were washed twice with cold PBS and processed for RNA extraction using the RNAeasy kit (Quiagen Inc., Valencia, CA, USA) according to the manufacturer's instructions. In some experiments, cells were pretreated for 90 min with NGF (100 ng/ml) prior to treatment with actinomycin-D (5 mg/ml) or pretreated for 15 min with cycloheximide (5 mg/ml) prior to NGF (100 ng/ml) treatment. Total RNA (15-20 mg) was electrophoretically fractionated in 1% agar/formaldehyde gels and transferred to Nytran s N membrane (Schleicher & Schuell, Keene, NH, USA). The blots were crosslinked by exposure to UV light. N-myc, c-fos and GAPDH cDNAs were radiolabeled with [a-32 P]dCTP using random primer methods. Prehybridization was performed for 1 h at 681C in prehybridization solution (CLONTECH, Palo Alto, CA, USA), followed by hybridization with radiolabeled probes for 1 h at 681C and washed as previously described (Thiele et al., 1985) . Membranes were exposed to X-ray Biomax-MS film (Kodak) with an intensifying screen. Quantitative densitometric analysis was performed on appropriately exposed autoradiograms using NIH Image.
Plasmids and transient transfection
Plasmids containing pMCL#MEK1 (vector, wild-type MEK1, constitutively activated MEK1) were provided by Dr NG Ahn (Department of Chemistry and Biochemistry, University of Colorado, Boulder, CO, USA; Mansour et al., 1994) . Five million LA1-15N cells were transfected by electroporation in 200 ml media with 10 mg DNA plasmid in a 0.2-cm cuvette at 960 mF capacitance and 150 V. Eight million KCNR cells were transfected by electroporation in 400 ml media with 20 mg DNA plasmid in 0.4-cm cuvette at 960 mF capacitance and 300 V. After 48 h, cells were lysed with 1% NP-40 lysis buffer and protein expression evaluated by Western blot analysis.
